Loading stock data…
ALC
$74.09-0.78 (-1.04%)
Market ClosedLast close May 1
Alcon Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alcon Inc. in the Healthcare sector is trading at $74.09. The stock is currently near its 52-week low of $71.55, remaining 6.6% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why ALC maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$74.09
Potential Downside
51.1%
Whystock Fair Value$36.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$94.43+27.5%
Range$71.00 – $113.00
Fundamentals
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Strong income play. Yield provides a meaningful total return floor.
46.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.45%
Volume
Today's trading volume
1.34M
Recent News
Alcon Board Change And Vision Research Progress Shape Investor Expectations
Alcon (SWX:ALC) has elected R. Scott Herren as a new independent member of its Board of Directors. The company is collaborating to present new data on AIM+ CSF visual assessment technology at a major vision research conference. These developments highlight both a change in boardroom oversight and a focus on advancing clinical tools in ophthalmology. Alcon comes into these announcements with its shares at CHF58.22 and a value score of 3, which may frame how some investors view the risk and...
ISRG Stock Up as Q1 Earnings & Sales Beat Estimates on Procedure Growth
ISRG jumps after Q1 EPS and revenues beat estimates as da Vinci and Ion procedure growth powers recurring sales and da Vinci 5 placements.
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential
The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential upside. Supporters connect this $10 mark to their view that ALLY System adoption can return to patterns seen before the Alcon deal was announced, while skeptics question whether that setup already bakes in optimistic execution. As you read on, you will see how both the bullish...
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat
ABT slips 4% despite Q1 beats as margin pressure, Nutrition weakness and lowered 2026 EPS guidance weigh on investor sentiment.
Is it a Prudent Move to Retain IDXX Stock in Your Portfolio Now?
IDEXX rides on strong diagnostics growth and software momentum, but FX pressure and weak solvency cloud its outlook - should investors hold now?